Contact: Jennifer Gutierrez
Mount Sinai Press Office
Mount Sinai Study Reveals New Genetic Link to Heart Disease
Findings may help improve risk prediction tools for cardiovascular disease
Newswise — New York, NY (June 18, 2019) — A collaboration involving the Icahn School of Medicine at Mount Sinai, the German Heart Center Munich, AstraZeneca, and Karolinska Institutet in Sweden has demonstrated that more than 30 percent of heart disease risk stems from genetic factors, much more than was previously understood. The study findings, published today in the Journal of the American College of Cardiology, introduce the biology of gene networks as means to better understand the heritability and genetic underpinnings of heart disease.
Coronary artery disease (CAD), the most common type of heart disease and one of the leading causes of death worldwide, forms plaque in the walls of the arteries that supply blood to the heart. A complete blockage of these arteries can lead to a heart attack or stroke.
Before this study, more than a decade of genome-wide-association studies (GWAS)—the analysis of genetic risk codes found more frequently in people with a particular trait, such as heart disease—had indicated that less than a quarter of CAD was considered inheritable. Meanwhile, the heritability contribution (if any) of genetic variants in gene regulatory networks (GRNs)—a set of genes that interact with each other to control a particular cell function—was unknown. In light of this, researchers used tissue data from two separate studies of individuals with CAD to determine whether genetic variants that regulate GRNs make independent contributions to the risk of heart disease.
Across vascular and metabolic tissue data, researchers identified and replicated 28 independent GRNs active in CAD and determined that the genetic variation in these networks contributed to the inherited risk of the heart disease by an additional 11 percent—adding to the 22 percent attributable risk previously identified by GWAS. This newfound contribution boosts the heritability of CAD to approximately 32 percent, spotlighting the important role played by interactions between internal environments and genetic variants—mediated by regulatory networks—in the development of heart disease.
“The results of this study demonstrate that the risk of heart disease is a concerted result of interactions between genetic variants and biological environments,” said Johan LM Björkegren, Professor of Medicine (Cardiology), and Genetics, at the Icahn School of Medicine at Mount Sinai. “By understanding the complex relationship between the two, we’ve created a framework for identifying new risk genes in disease-relevant tissues leading to heart disease, which in turn will allow for more effective risk prediction, clinical intervention, and eventually, opportunities for novel and more effective therapies.”
Another researcher involved in the study, Heribert Schunkert, MD, Professor of Cardiology at the German Heart Center in Munich, added, “A mystery of recent research was the fact that many genes contributing to the genetics of coronary artery disease affect mechanisms that were not expected in this context. The present study leads to a much better understanding of how these genes work together in precipitating or preventing the disease.”
Li-Ming Gan, Vice President of Early Clinical Development, Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals, AstraZeneca, commented that this study “provides new insight into the heritability of coronary artery disease, adding a substantial number of genetic variants contributing to its heritability. Further analysis may help explain the disease’s etiology and give novel insights on how to prevent its development.”
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.